JP2018507910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507910A5 JP2018507910A5 JP2017560893A JP2017560893A JP2018507910A5 JP 2018507910 A5 JP2018507910 A5 JP 2018507910A5 JP 2017560893 A JP2017560893 A JP 2017560893A JP 2017560893 A JP2017560893 A JP 2017560893A JP 2018507910 A5 JP2018507910 A5 JP 2018507910A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- odc1
- genotype
- pharmacotherapy
- drug therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 14
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 14
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 14
- 238000002651 drug therapy Methods 0.000 claims 12
- 238000001050 pharmacotherapy Methods 0.000 claims 12
- 108700028369 Alleles Proteins 0.000 claims 10
- 238000012360 testing method Methods 0.000 claims 8
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 7
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 102000004031 Carboxy-Lyases Human genes 0.000 claims 1
- 108090000489 Carboxy-Lyases Proteins 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- FJPAMFNRCFEGSD-UHFFFAOYSA-N eflornithine hydrochloride monohydrate Chemical compound O.Cl.NCCCC(N)(C(F)F)C(O)=O FJPAMFNRCFEGSD-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115413P | 2015-02-12 | 2015-02-12 | |
| US62/115,413 | 2015-02-12 | ||
| US201562154804P | 2015-04-30 | 2015-04-30 | |
| US62/154,804 | 2015-04-30 | ||
| PCT/US2016/017751 WO2016130918A1 (en) | 2015-02-12 | 2016-02-12 | Methods for treating neuroblastoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507910A JP2018507910A (ja) | 2018-03-22 |
| JP2018507910A5 true JP2018507910A5 (cg-RX-API-DMAC7.html) | 2019-03-22 |
Family
ID=56615061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560893A Pending JP2018507910A (ja) | 2015-02-12 | 2016-02-12 | 神経芽細胞腫を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20190046484A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3256117A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018507910A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2976106A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1248133A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016130918A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040263T2 (hu) | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| CA2952771A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| CN109069462A (zh) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| AU2017339781B2 (en) * | 2016-10-06 | 2022-03-17 | Orbus Therapeutics, Inc. | Formulations for administration of eflornithine |
| MX2021004710A (es) * | 2018-10-24 | 2021-06-04 | Navitor Pharm Inc | Compuestos polimorficos y usos de los mismos. |
| US10945981B2 (en) | 2019-05-17 | 2021-03-16 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| CN120548176A (zh) | 2022-11-20 | 2025-08-26 | 苏黎士大学 | 多胺途径抑制剂药物与脯氨酸/精氨酸饮食限制的组合 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142218A0 (en) * | 1998-09-23 | 2002-03-10 | Lonza Ag | PROCESS FOR THE PREPARATION OF (-) -α- DIFLUORMETHYLORNITHINE MONOHYDROCHLORIDE MONOHYDRATE |
| US6753422B2 (en) * | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| US6730809B2 (en) * | 2001-08-29 | 2004-05-04 | Women First Healthcare, Inc. | Processes for the production of α-difluoromethyl ornithine (DFMO) |
| ES2330860T3 (es) * | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
| US20100009929A1 (en) * | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| WO2007075673A1 (en) * | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
| FR2906808B1 (fr) * | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| US8829021B2 (en) * | 2007-08-01 | 2014-09-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treatment of pediatric tumors |
| CA2761946A1 (en) * | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California, A California Corporation | Carcinoma diagnosis and treatment, based on odc1 genotype |
| EP2432553A2 (en) * | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
| US20110256161A1 (en) * | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
| CN103347894B (zh) * | 2010-06-19 | 2017-05-10 | 纪念斯隆-凯特林癌症中心 | 抗gd2抗体 |
| HUE040263T2 (hu) * | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| GB2513299A (en) * | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
| EP2968545B1 (en) * | 2013-03-15 | 2019-03-06 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
| CA2952771A1 (en) * | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
-
2016
- 2016-02-12 WO PCT/US2016/017751 patent/WO2016130918A1/en not_active Ceased
- 2016-02-12 HK HK18107762.1A patent/HK1248133A1/zh unknown
- 2016-02-12 CA CA2976106A patent/CA2976106A1/en not_active Abandoned
- 2016-02-12 US US15/550,595 patent/US20190046484A1/en not_active Abandoned
- 2016-02-12 JP JP2017560893A patent/JP2018507910A/ja active Pending
- 2016-02-12 EP EP16749956.5A patent/EP3256117A4/en not_active Withdrawn
-
2021
- 2021-01-13 US US17/147,697 patent/US20210378999A1/en not_active Abandoned
-
2023
- 2023-08-04 US US18/230,601 patent/US20240165063A1/en not_active Abandoned
-
2024
- 2024-12-23 US US18/999,227 patent/US20250127742A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507910A5 (cg-RX-API-DMAC7.html) | ||
| McQuay et al. | Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty | |
| Hoy et al. | Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation | |
| Diemunsch et al. | Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery | |
| Bionorica | Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis | |
| Laha et al. | Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial | |
| Zhao et al. | Chronic resveratrol treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with mononeuropathy: involvement of serotonergic system | |
| Candiotti et al. | Randomized, double-blind, placebo-controlled study of intravenous amisulpride as treatment of established postoperative nausea and vomiting in patients who have had no prior prophylaxis | |
| Koh et al. | Postoperative pain and intravenous patient-controlled analgesia-related adverse effects in young and elderly patients: a retrospective analysis of 10,575 patients | |
| Bateman et al. | Recent advances in COPD disease management with fixed-dose long-acting combination therapies | |
| Bajwa et al. | Comparison of intrathecal clonidine and fentanyl in hyperbaric bupivacaine for spinal anesthesia and postoperative analgesia in patients undergoing lower abdominal surgeries | |
| Sandercock et al. | A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial | |
| JP2012526852A5 (cg-RX-API-DMAC7.html) | ||
| Kraemer et al. | Pharmacologic management of acute pediatric pain | |
| Statler et al. | Ephedrine | |
| Parvathy et al. | Matrix metalloproteinase inhibitor COL-3 prevents the development of paclitaxel-induced hyperalgesia in mice | |
| Maltais et al. | P250 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD | |
| Majumdar et al. | Intravenous paracetamol infusion: Superior pain management and earlier discharge from hospital in patients undergoing palliative head-neck cancer surgery | |
| Shaikh et al. | Comparison of epidural clonidine and dexmedetomidine for perioperative analgesia in combined spinal epidural anesthesia with intrathecal levobupivacaine: a randomized controlled double-blind study | |
| Mahajan et al. | Study to compare the effect of oral, rectal, and intravenous infusion of paracetamol for postoperative analgesia in women undergoing cesarean section under spinal anesthesia | |
| CN100418533C (zh) | 环加氧酶-2抑制剂和阿片剂的药物组合体 | |
| Fitzgerald et al. | Outpatient medication use and implications for dental care: guidance for contemporary dental practice | |
| Sturn et al. | Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients | |
| Daniels et al. | Clinical efficacy and safety of tapentadol immediate release in the postoperative setting | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |